HeartBeam Schedules Third Quarter 2026 Earnings Conference Call
HeartBeam, Inc. announced it will host a conference call to discuss its third quarter 2026 financial results on November 12, 2026.
Stocks · News reference
HeartBeam Receives FDA Clearance for Acute Myocardial Infarction Assessment Technology
HeartBeam, Inc. has received U.S. Food and Drug Administration (FDA) clearance for its technology designed to assess acute myocardial infarction.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HeartBeam Announces Positive Heart Attack Pilot Study Results at TCT 2026
HeartBeam reported positive results from a pilot study presented at the TCT 2026 conference, demonstrating that its patient-recorded 3D ECG technology is as accurate as a standard 12-lead ECG.
HeartBeam to Present Results of ALIGN-ACS Study for Heart Attack Assessment at TCT 2026
HeartBeam, Inc. announced it will present the results of its ALIGN-ACS study, which evaluates the company's technology for heart attack assessment, at the TCT 2026 conference on November 1, 2026.
HeartBeam Completes Enrollment for HEADSTART-ACS Study
HeartBeam, Inc. has successfully completed patient enrollment for its 486-patient HEADSTART-ACS study ahead of the original schedule.
HeartBeam Completes Enrollment Ahead Of Schedule In 486-Patient HEADSTART-ACS Study
HEADSTART-ACS study conducted in collaboration with Indonesia’s National Cardiovascular Center in world’s fourth most populous country, representing strategically significant market of 288 million peopleData analysis is
HeartBeam Named Contributing Partner In Launch Of EXIT-CVD Research Project, Co-Funded By European Union Innovative Health Initiative And Industry Partners
HeartBeam joins Philips, Medtronic, GE HealthCare and other global healthcare leaders in the EU-funded EXIT-CVD research consortiumHeartBeam will lead the HEART-CHECK Study, one of the project’s 22 studiesHEART-CHECK